N-NOSE
Commercial- Indications
- Cancer detection
Company intelligence / Profile preview
N-NOSE has demonstrated efficacy for early detection of multiple cancers—including gastrointestinal and hematologic malignancies—using a non-invasive urine test with C. elegans nematodes as biological sensors. Peer-reviewed clinical research supports its accuracy and utility for population-wide screening.[2][5] Over one clinical trial completed in collaboration with the University of Tokyo for gastrointestinal cancers.[5]
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hirotsu Bio Science.